Sign up to save your podcasts
Or
Share Dan Elton on the A4LI D.C Fly-In Event
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Dan Elton on the A4LI D.C Fly-In Event
On Sunday, March 24, 2024, at 1 p.m. U.S. Pacific Time, the U.S. Transhumanist Party invites its Director of Scholarship, Dr. Dan Elton, to provide an overview of key discussions at the Alliance for Longevity Initiatives (A4LI) 2024 D.C. Fly-In Event, which he attended on March 20-21, 2024.
The A4LI Fly-In included a longevity industry discussion with ARPA-H, the new Advanced Research Projects Agency for Health, and a Longevity Industry Science Congressional Briefing. It was described by A4LI as follows:
“The biological aging process is the primary risk factor for the top causes of non-accidental death in the United States, including heart disease, cancers, COVID-19, stroke, respiratory illnesses and Alzheimer’s. In total, chronic, age-driven health conditions that require ongoing medical care and treatment incur $3.7 trillion in annual healthcare spending. As people live longer, a growing proportion of our population suffer from more than one age-related condition at a time, further exacerbating the healthcare system.”
“Because aging is the driver of chronic diseases, therapies that directly target aging physiology could prevent or cure multiple chronic age-related diseases. Researchers in the biology of aging are beginning to understand how the biological processes of aging promote disease, and dozens of biotechnology companies are applying that understanding to delay the onset and progression of age-associated health problems. Such interventions, generally termed “longevity medicine,” have the potential to dramatically decrease both mortality and healthcare costs, likely to a greater extent than even the complete cure of any one disease, while alleviating suffering and improving quality of life — revolutionizing healthcare for all Americans.”
“Recognizing that there is a need for federal investment and commercialization in the longevity medicine space, the Alliance for Longevity Initiatives [hosted its] inaugural D.C. Fly-In, which [included] the first ever Longevity Science Briefing on March 21st, 2024. ”
The A4LI Fly-In included a longevity industry discussion with ARPA-H, the new Advanced Research Projects Agency for Health, and a Longevity Industry Science Congressional Briefing. It was described by A4LI as follows:
“The biological aging process is the primary risk factor for the top causes of non-accidental death in the United States, including heart disease, cancers, COVID-19, stroke, respiratory illnesses and Alzheimer’s. In total, chronic, age-driven health conditions that require ongoing medical care and treatment incur $3.7 trillion in annual healthcare spending. As people live longer, a growing proportion of our population suffer from more than one age-related condition at a time, further exacerbating the healthcare system.”
“Because aging is the driver of chronic diseases, therapies that directly target aging physiology could prevent or cure multiple chronic age-related diseases. Researchers in the biology of aging are beginning to understand how the biological processes of aging promote disease, and dozens of biotechnology companies are applying that understanding to delay the onset and progression of age-associated health problems. Such interventions, generally termed “longevity medicine,” have the potential to dramatically decrease both mortality and healthcare costs, likely to a greater extent than even the complete cure of any one disease, while alleviating suffering and improving quality of life — revolutionizing healthcare for all Americans.”
“Recognizing that there is a need for federal investment and commercialization in the longevity medicine space, the Alliance for Longevity Initiatives [hosted its] inaugural D.C. Fly-In, which [included] the first ever Longevity Science Briefing on March 21st, 2024. ”
View all episodes
By KGRA Digital BroadcastingOn Sunday, March 24, 2024, at 1 p.m. U.S. Pacific Time, the U.S. Transhumanist Party invites its Director of Scholarship, Dr. Dan Elton, to provide an overview of key discussions at the Alliance for Longevity Initiatives (A4LI) 2024 D.C. Fly-In Event, which he attended on March 20-21, 2024.
The A4LI Fly-In included a longevity industry discussion with ARPA-H, the new Advanced Research Projects Agency for Health, and a Longevity Industry Science Congressional Briefing. It was described by A4LI as follows:
“The biological aging process is the primary risk factor for the top causes of non-accidental death in the United States, including heart disease, cancers, COVID-19, stroke, respiratory illnesses and Alzheimer’s. In total, chronic, age-driven health conditions that require ongoing medical care and treatment incur $3.7 trillion in annual healthcare spending. As people live longer, a growing proportion of our population suffer from more than one age-related condition at a time, further exacerbating the healthcare system.”
“Because aging is the driver of chronic diseases, therapies that directly target aging physiology could prevent or cure multiple chronic age-related diseases. Researchers in the biology of aging are beginning to understand how the biological processes of aging promote disease, and dozens of biotechnology companies are applying that understanding to delay the onset and progression of age-associated health problems. Such interventions, generally termed “longevity medicine,” have the potential to dramatically decrease both mortality and healthcare costs, likely to a greater extent than even the complete cure of any one disease, while alleviating suffering and improving quality of life — revolutionizing healthcare for all Americans.”
“Recognizing that there is a need for federal investment and commercialization in the longevity medicine space, the Alliance for Longevity Initiatives [hosted its] inaugural D.C. Fly-In, which [included] the first ever Longevity Science Briefing on March 21st, 2024. ”
The A4LI Fly-In included a longevity industry discussion with ARPA-H, the new Advanced Research Projects Agency for Health, and a Longevity Industry Science Congressional Briefing. It was described by A4LI as follows:
“The biological aging process is the primary risk factor for the top causes of non-accidental death in the United States, including heart disease, cancers, COVID-19, stroke, respiratory illnesses and Alzheimer’s. In total, chronic, age-driven health conditions that require ongoing medical care and treatment incur $3.7 trillion in annual healthcare spending. As people live longer, a growing proportion of our population suffer from more than one age-related condition at a time, further exacerbating the healthcare system.”
“Because aging is the driver of chronic diseases, therapies that directly target aging physiology could prevent or cure multiple chronic age-related diseases. Researchers in the biology of aging are beginning to understand how the biological processes of aging promote disease, and dozens of biotechnology companies are applying that understanding to delay the onset and progression of age-associated health problems. Such interventions, generally termed “longevity medicine,” have the potential to dramatically decrease both mortality and healthcare costs, likely to a greater extent than even the complete cure of any one disease, while alleviating suffering and improving quality of life — revolutionizing healthcare for all Americans.”
“Recognizing that there is a need for federal investment and commercialization in the longevity medicine space, the Alliance for Longevity Initiatives [hosted its] inaugural D.C. Fly-In, which [included] the first ever Longevity Science Briefing on March 21st, 2024. ”